Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded?

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Critical reviews in oncology/hematology

• Publication date

  2016-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.critrevonc.2016.02.005PMID 26907512
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Synergistic antitumour effects of rapamycin and oncolytic reovirus

  2018cited by this paper
• Controversies in Oncology : Economics of Oncology Practice Ramucirumab for Colon Cancer and the Problem of Rising Prices Independent of Benefits

  2015cited by this paper
• Chronic exposure of VEGF inhibitors promotes the malignant phenotype of colorectal cancer cells.

  2015cited by this paper
• Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: Implications for clinical management

  2015cited by this paper
• A Combinatory Strategy for Detection of Live CTCs Using Microfiltration and a New Telomerase-Selective Adenovirus

  2015cited by this paper
• Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial.

  2015cited by this paper
• Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: a multicentric retrospective analysis

  2015cited by this paper
• Two decades of the oncologist.

  2015cited by this paper
• FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study†

  2015cited by this paper
• Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.

  2015cited by this paper
• Antiangiogenic Therapy Impedes Infiltration by CD4+ and CD8+ Cells Into an Early Colon Tumor

  2015cited by this paper
• The "angiogenetic ladder", step-wise angiogenesis inhibition in metastatic colorectal cancer.

  2014cited by this paper
• The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management

  2014cited by this paper
• Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.

  2014cited by this paper
• Vasculature analysis of patient derived tumor xenografts using species-specific PCR assays: evidence of tumor endothelial cells and atypical VEGFA-VEGFR1/2 signalings

  2014cited by this paper
• Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.

  2014cited by this paper
• Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.

  2014influential reference
• Intrinsic bevacizumab resistance is associated with prolonged activation of autocrine VEGF signaling and hypoxia tolerance in colorectal cancer cells and can be overcome by nintedanib, a small molecule angiokinase inhibitor

  2014cited by this paper
• Clinical advances in the development of novel VEGFR2 inhibitors.

  2014cited by this paper
• Anti‐VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts

  2014cited by this paper
• 1582PNATURAL BEVACIZUMAB RESISTANCE IS ASSOCIATED WITH HYPOXIA TOLERANCE AND PROLONGED ACTIVATION OF AUTOCRINE VEGF SIGNALING IN COLORECTAL CANCER CELLS AND CAN BE OVERCOME BY NINTEDANIB, A TRIPLE ANGIOKINASE INHIBITOR.

  2014cited by this paper
• Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.

  2014cited by this paper
• Colorectal Cancer Cells Refractory to Anti-VEGF Treatment Are Vulnerable to Glycolytic Blockade due to Persistent Impairment of Mitochondria

  2013cited by this paper
• Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.

  2013cited by this paper
• Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings.

  2013influential reference
• Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours.

  2013cited by this paper
• A preclinical and clinical review of aflibercept for the management of cancer.

  2012cited by this paper
• Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.

  2012cited by this paper
• Concordant release of glycolysis proteins into the plasma preceding a diagnosis of ER+ breast cancer.

  2012cited by this paper
• The Role of LDH Serum Levels in Predicting Global Outcome in HCC Patients Undergoing TACE: Implications for Clinical Management

  2012cited by this paper
• Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study.

  2012cited by this paper
• O-0024 Phase 2 Randomized, Noncomparative, Open-Label Study of Aflibercept and Modified Folfox6 in the First-Line Treatment of Metastatic Colorectal Cancer (AFFIRM)

  2012cited by this paper
• Phase II Clinical and Pharmacokinetic Study of Aflibercept in Patients with Previously Treated Metastatic Colorectal Cancer

  2012cited by this paper
• Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients

  2012cited by this paper
• Anti-VEGF/VEGFR therapy for cancer: reassessing the target.

  2012cited by this paper
• Ramucirumab (IMC-1121B): Monoclonal Antibody Inhibition of Vascular Endothelial Growth Factor Receptor-2

  2011cited by this paper
• Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy

  2011cited by this paper
• Effects of Anti-VEGF Treatment Duration on Tumor Growth, Tumor Regrowth, and Treatment Efficacy

  2010cited by this paper
• Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease.

  2010cited by this paper
• Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance.

  2010cited by this paper
• Targeted therapies: Goldie–Coldman and bevacizumab beyond disease progression

  2009cited by this paper
• Positive and Negative Modulation of Angiogenesis by VEGFR1 Ligands

  2009cited by this paper
• Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE).

  2008cited by this paper
• Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels.

  2007cited by this paper
• Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.

  2007cited by this paper
• Inaugural Article: VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade

  2007cited by this paper
• Synergistic activity of aflibercept (VEGF Trap) in combination with 5-fluorouracil and irinotecan in preclinical tumor models

  2007cited by this paper
• AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

  2007cited by this paper
• Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for Metastatic Colorectal Cancer

  2006cited by this paper
• Synergistic Antitumor Effects of Combined Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor Receptor-2 Targeted Therapy

  2006cited by this paper
• Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.

  2006cited by this paper
• Vascular Endothelial Growth Factor Trap Combined with Paclitaxel Strikingly Inhibits Tumor and Ascites, Prolonging Survival in a Human Ovarian Cancer Model

  2005cited by this paper
• Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

  2004cited by this paper
• Angiogenesis: Tumorigenesis and the angiogenic switch

  2003cited by this paper
• VEGF-Trap: A VEGF blocker with potent antitumor effects

  2002cited by this paper

• Investigation on LASSBio‐1971 and LASSBio‐1974 Cellular Cytotoxic Mechanism and Their Comparative DMPK Profile

  2025cites this paper
• Prediction of Response to Anti-Angiogenic Treatment for Advanced Colorectal Cancer Patients: From Biological Factors to Functional Imaging

  2024cites this paper
• Circulating tumour DNA analysis and new uses of anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer

  2024cites this paper
• Evidence-Based Second-Line Treatment in RAS Wild-Type/Mutated Metastatic Colorectal Cancer in the Precision Medicine Era

  2021cites this paper
• Targeting Cytoprotective Autophagy to Enhance Anticancer Therapies

  2021cites this paper
• Are All Anti-Angiogenic Drugs the Same in the Treatment of Second-Line Metastatic Colorectal Cancer? Expert Opinion on Clinical Practice

  2021influential citation
• Anti-angiogenic Targeting in Metastatic Colorectal Cancer Therapy

  2019cites this paper
• Safety and Tolerability of Anti-Angiogenic Protein Kinase Inhibitors and Vascular-Disrupting Agents in Cancer: Focus on Gastrointestinal Malignancies

  2019cites this paper
• Transient Disappearance of RAS Mutant Clones in Plasma: A Counterintuitive Clinical Use of EGFR Inhibitors in RAS Mutant Metastatic Colorectal Cancer

  2019cites this paper
• Existing anti-angiogenic therapeutic strategies for patients with metastatic colorectal cancer progressing following first-line bevacizumab-based therapy

  2019cites this paper
• Autophagy Inhibition Promotes Bevacizumab-induced Apoptosis and Proliferation Inhibition in Colorectal Cancer Cells

  2018cites this paper
• Genetics and current treatment strategy of colorectal cancer

  2017cites this paper
• Aflibercept, a New Way to Target Angiogenesis in the Second Line Treatment of Metastatic Colorectal Cancer (mCRC)

  2016cites this paper
• Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies

  2016cites this paper